Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 1/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 3/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | TPH1 | P17752 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31595870 | 0.86 | RAB9A (0.34) | UBE2MDCUN1D1AOC3FAAHCHRNA4 | |
| SCHEMBL26054880 | 0.85 | AOC3 (0.34) | UBE2MDCUN1D1AOC3CHRNA4CHRNB2 | |
| SCHEMBL26053991 | 0.85 | GRM5 (0.34) | UBE2MDCUN1D1AOC3HSD11B1TPH1 | |
| SCHEMBL26056977 | 0.84 | FAAH (0.33) | UBE2MDCUN1D1AOC3FAAHTPH1 | |
| SCHEMBL31595776 | 0.84 | FAAH (0.33) | UBE2MDCUN1D1AOC3FAAHTPH1 | |
| SCHEMBL26054886 | 0.83 | UBE2M (0.35) | UBE2MDCUN1D1AOC3HSD11B1NAAA | |
| SCHEMBL31596204 | 0.82 | GRM5 (0.36) | UBE2MDCUN1D1AOC3HSD11B1NAAA | |
| SCHEMBL31596183 | 0.82 | UBE2M (0.32) | UBE2MDCUN1D1AOC3HSD11B1NAAA | |
| SCHEMBL26054963 | 0.82 | UBE2M (0.32) | UBE2MDCUN1D1AOC3HSD11B1NAAA | |
| SCHEMBL26054888 | 0.82 | AOC3 (0.33) | UBE2MDCUN1D1AOC3HSD11B1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2023164237-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | UBE2M 4437/4885DCUN1D1 2773/4885AOC3 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.